You've chosen Americas as your location.

To clear your location selection and return to IPS Global, click below.

Return to IPS Global

You've chosen Americas as your location.

Thank you for choosing a location. This will help us show you the information that matters the most to you.

Continue Change Selection

 

INFECTION PREVENTION THROUGH STERILITY ASSURANCE & MICROBIOLOGICAL QUALITY: REFLECTIONS FROM A PATIENT & INDUSTRY SME

Tuesday, April 9, 2024

DESCRIPTION OF MEETING: “Infection Prevention through Sterility Assurance & Microbiological Quality: Reflections from a Patient & Industry SME”

SPEAKER:
Dawn Nestola, Director Sterility Assurance & Microbiological Quality, GlazoSmithKline.

OVERVIEW OF PRESENTATION:
Sterility assurance and microbiological quality (SA & MQ) are fundamental to the production of pharmaceuticals/biopharmaceuticals, advanced therapy medicinal products (ATMPs), medical devices, and over-the-counter (OTC) medicines, contributing to product quality, safety, and promoting infection prevention in patients and consumers.

Recent updates to EU Annex 1 have mandated that manufacturers develop and actively maintain a robust contamination control strategy (CCS), and end-to-end SA & MQ are core to this regulatory requirement. Although a CCS primarily focuses on activities directly controlled by a manufacturer, elements that extend beyond the bounds of a GMP facility's four walls are just as important. In fact, SA & MQ begin elsewhere, with suppliers and sub-suppliers who provide, for example, device components and subcomponents, packaging components, manufacturing consumables (often sterile single-use systems), sterilization services, and raw materials, including aseptically collected patient cells (via apheresis), which may be the primary raw material in an ATMP. Likewise, SA & MQ do not terminate when a released product leaves the manufacturing facility, bound for a distribution center or customer. In contrast, SA & MQ end with each successful patient or consumer outcome when a product of appropriate microbiological quality (for its intended use) is consumed and/or properly used by the medical practitioner or recipient.

The speaker's presentation will focus on her patient experience with a life-threatening medical condition and offer reflections, through the lens of an industry SME, on her treatment journey and how SA & MQ contributed to her positive patient outcome.

For more information visit the PDA Delaware Valley Chapter webpage.

close

Choose Your Location

To customize your experience, select an IPS region or country to view specific information based on your location.

  • Americas
  • United States
  • Canada
  • Brazil
  • All Other Countries

You’ve chosen as your location.

Thank you for choosing a location. This will help us show the information that means to most to you. Continue to the homepage to view featured projects, and happenings specific to your location.

Continue

We use cookies to personalize and enhance your experience on our site. Visit our Privacy Policy to learn more.